GSA Press Release

Axolotl Biologix Products Approved and Added to the General Services Administration’s Federal Supply Schedule

Award Allows the VA, Indian Health Services and Other Federal Agencies to Order and

Prescribe Axolotl Biologix Products

Phoenix, AZ (January 14, 2019) - Axolotl Biologix, a biotechnology leader in regenerative

medicine, is proud to announce that the General Services Administration (GSA) has added

Axolotl Biologix’s products to the Federal Supply Schedule (FSS).

The GSA award will allow physicians and staff of federal agencies, such as the Veterans

Administration and Indian Health Services, to order Axolotl Biologix products when seeking

remedies to promote repair or regeneration of damaged tissues. Products now available through

the FSS to address these issues include Axolotl Biologix’s lines of regenerative fluid and

membrane allografts.

“We are thrilled that Axolotl Biologix products have been added to the GSA’s Federal Supply

Schedule which allows government agencies to order our products as they develop treatment

plans for their patients,” said Phillip Larson, President of Axolotl Biologix. “Approval and

inclusion in the FSS will provide patients and their physicians additional care options.”

Axolotl Biologix currently has three products available on the GSA’s FSS and have begun the

process to add additional products in the months and years ahead. Its liquid allograft products

come in both cryopreserved and ambient temperatures giving medical facilities more flexibility

to have products on-hand as needed, while Axolotl Biologix’s membrane allograft products

assist with wound care.

GMP- Government Marketing & Procurement, LLC assisted Axolotl Biologix in the process to be added to the GSA’s FSS.

About Axolotl Biologix:

Axolotl Biologix, Inc. is an innovative biotechnology leader in regenerative medicine through

research, technology and clinical application. Axolotl Biologix is expanding the human body’s

ability to regenerate by developing and manufacturing regenerative human cell and tissue

medical technologies that are disrupting traditional, more invasive, painful and expensive

treatment protocols. For more information, visit www.axobio.com

###

Media Contact:

Josh Weiss

10 to 1 Public Relations

josh@10to1pr.com

480-789-0743

Laura Slawny

10 to 1 Public Relations

laura@10to1pr.com

480-868-9423

Axolotl Shot™ Press Release

Axolotl Biologix Launches New Axolotl Shot™ For Wound Care

Pre-Loaded Regenerative Medicine Syringe Saves Doctors Time and Money

 

Phoenix, AZ (Dec. 5, 2018) - Axolotl Biologix, an innovative biotechnology leader in regenerative medicine, is proud to announce the launch of Axolotl Shot™, an ambient temperature regenerative fluid preloaded into a syringe for ease of use by physicians.

Axoltol Biologix is the first to market a preloaded syringe containing a regenerative fluid that is manufactured using the proprietary BioSym™ process to yield growth factors and cytokines known to stimulate cellular growth and repair. It offers significant therapeutic benefits to help facilitate repair and regeneration of damaged cells and tissues


 

“Our new Axolotl Biologix treatment option uses the latest advances in biotechnology to improve patient outcomes while making it more convenient for physicians,” said Dr. Robert Kellar, Chief Science Officer.  “The Axolotl Shot is preloaded in 1mL and 2mL volumes, terminally irradiated for use in surgical applications, and since it can be stored at room temperature there is no storage concerns or down time waiting for product to thaw.”

 

This new option benefits consumers because it can be applied during a same-day outpatient visit, helping patients avoid the costs, pain and downtime associated with surgery.

“Axolotl Biologix is excited to introduce the Axolotl Shot which has potential clinical benefits in a variety of applications that will help physicians, orthopods, and wound care specialists save time and money treating patients,” said Phillip Larson, President of Axolotl Biologix.

Axolotl Shot is a regenerative fluid derived from the amniotic components of the placenta to promote regeneration and repair of damaged or degenerated tissues. Donor tissue is recovered and processed aseptically in accordance with all FDA guidelines and quality assurance standards in a controlled environment.

About Axolotl Biologix:

Axolotl Biologix, Inc. is an innovative biotechnology leader in regenerative medicine through research, technology and clinical application. Axolotl Biologix is expanding the human body’s ability to regenerate by developing and manufacturing regenerative human cell and tissue medical technologies that are disrupting traditional, more invasive, painful and expensive treatment protocols. For more information, visit www.axobio.com